二丙酸倍氯米松鼻喷雾剂联合氯雷他定治疗常年性变应性鼻炎临床研究  

Clinical study on combination of beclomethasone dipropionate nasal spray & loratadine to perennial allergic rhinitis

作　　者：叶瑞艳[1] 吴艳巧[1] 汪柳燕[1] 

机构地区：[1]中国石油勘探开发研究院卫生所,北京100083

出　　处：《中国伤残医学》2013年第8期52-54,共3页Chinese Journal of Trauma and Disability Medicine

摘　　要：目的:探讨二丙酸倍氯米松鼻喷雾剂联合氯雷他定治疗常年性变应性鼻炎的疗效及安全性。方法:对100例临床确诊为变应性鼻炎的患者随机分成3组:氯雷他定治疗组34例,二丙酸倍氯米松鼻喷雾剂治疗组33例,联合治疗组33例。分别于治疗前,第7天,第14天对鼻部和非鼻部症状、体征进行评估计分,进行统计学处理评价疗效;试验前后进行脉搏、血压、血、尿常规、肝功能、肾功能、血糖检测并记录全身及局部不良反应,评价治疗的安全性。结果:3组均有效,且无明显的不良反应,联合治疗组疗效优于二丙酸倍氯米松治疗组和氯雷他定组。结论:HI受体拮抗剂的抗组胺作用与皮质类固醇抗炎作用结合,能更有效地治疗常年性变应性鼻炎,既能治疗急性反应症状,且临床应用安全性好。Objective：To investigate efficacy and safety of combination treatment of beclomethasone dipropionate nasal spray ＆ loratadine to perennial allergic rhinitis patients. Methods： 100 allergic rhinitis patients were randomly divided into three groups： loratadine group, beclomethasone dipropionate group and combination therapy group . Scored before treatment ,7 days, 14 days with nasal and nonnasal symptoms to evaluate efficacy; collect pulse, blood pressure, blood rutine, urine rutine, liver function, kidney function and blood glucose before and after treatment and record systemic and local adverse reaction to evaluate the safety Results：all groups gained efficacy and safty, combination of beclomethasone dipropionate and chlorine gained more . Conclusion： Antihistamine was H1 receptor antagonist and eorticosteroid had anti - inflammatory effects, their combination gain more effective in the treatment of perennial allergic rhinitis, not only release symptoms of acute reaction but also had clinic safe.

关 键 词：二丙酸倍氯米松 氯雷他定 常年性变应性鼻炎 

分 类 号：R765.21[医药卫生—耳鼻咽喉科]